Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226793 · ClinicalTrials.gov registry record
Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 400
- Enrollment target
NCT05226793: Completed study, sponsored by Methodist Health System.
NCT05226793 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05226793 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 400 participants
- Enrollment target
Study Summary
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.
Primary Outcome
Enoxaparin dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2025-07-22 |
What the finished NCT05226793 record still lists
NCT05226793 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05226793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05226793 about?
NCT05226793 is a clinical study titled "Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients". Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxa...
What is the current status of trial NCT05226793?
This trial is currently completed. The enrollment target is 400 participants. The study started on 2021-11-17. Estimated completion is 2025-07-22.
Who is sponsoring clinical trial NCT05226793?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI